Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 14  |  Issue : 55  |  Page : 264-267

Evaluation of aphrodisiac activity of AHPL/AYCAP/0114 capsule in sexually sluggish male rats


1 Ari Healthcare Pvt. Ltd., Research and Development Center, Unit No. 401, International Biotech Park, BTS 2 Building, Chrysalis Enclave, 4th Floor, Plot No. 2A, MIDC Phase II, Hinjewadi, Pune, Maharashtra, India
2 Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Sant Tukaram Nagar, Pimpri, Pune, Maharashtra, India

Correspondence Address:
Sanjay U Nipanikar
R and D Center, Ari Healthcare Private Limited, Unit No. 401, International Biotech Park, BTS 2 Building, Chrysalis Enclave, 4th Floor, Plot No – 2A, MIDC Phase II, Hinjewadi, Pune - 411 057, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pm.pm_363_17

Rights and Permissions

Background: Male sexual dysfunction includes a wide range of problems such as erectile dysfunction and premature ejaculation, for which medical help is sought. The conventional use of various pharmacological and nonpharmacological measures are associated with multiple adverse events. Hence, a polyherbal formulation AHPL/AYCAP/0114 capsule was developed to provide safe and effective therapeutic option. Objectives: The aim of this study was to evaluate the aphrodisiac potential of AHPL/AYCAP/0114 capsule by assessing sexual behavior parameters such as mount frequency (MF), mount latency (ML), intromission frequency (IF), intromission latency (IL), ejaculation latency (EL), and ejaculation frequency (EF) in sexually sluggish male rats. Materials and Methods: Male Wistar rats were divided into six groups (n = 6) and treated with testosterone (30 mg/kg), sildenafil citrate (0.5 mg/kg), and AHPL/AYCAP/0114 capsule (110, 220, and 440 mg/kg) as Group II, Group III, and Group IV, V, and VI, respectively, for 28 days. Group I animals served as control. Then, they were introduced to sexually active female rats and their sexual behavior was recorded. Results: A significant increase in MF, IF, and EF was observed in all the AHPL/AYCAP/0114 capsule groups as compared to control group. A significant decrease in ML, IL, and EL was observed in all the AHPL/AYCAP/0114 capsule groups as compared to control group. AHPL/AYCAP/0114 capsule was well tolerated by rats. Discussion: Increase in MF, IF, and EF and reduction in ML, IL, and EL are indicative of increased sexual motivation and arousal and prolonged duration of coitus. This suggests enhanced sexual performance in sexually sluggish animals treated with AHPL/AYCAP/0114 capsule. Conclusion: It can be concluded that AHPL/AYCAP/0114 capsule possesses aphrodisiac activity and can be used in erectile dysfunction and loss of libido. Abbreviations used: (MF): Mount frequency; (ML): Mount latency; (IF): Intromission frequency; (IL): Intromission latency; (EL): Ejaculation latency; (EF): Ejaculation frequency; (ED): Erectile dysfunction; CPCSEA: Committee for the Purpose of Control And Supervision of Experiments on Animals.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1025    
    Printed25    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal